BioLine RX BLRX 深 滬
已收盤 07-02 16:00:00 美东时间
3.285
+0.115
+3.63%
華盛通- 最 高3.285
- 今 開3.22
- 成交量 5059股
- 最 低 3.1671
- 昨 收 3.17
- 總市值 1429.42万
- 52周最高 4.8551
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 2.15
- 委 比 -64.66%
- 總股本 435.14万
- 歷史最高 4122.00
- 量 比 0.43
- 振 幅 3.72%
- 歷史最低 2.15
- 每 手 1
- 風險率 0.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多电话会总结 ｜ BioLineRx(BLRX)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据BioLineRx业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **2026年第一季度财务表现：** - **营收**：50万美元，主要来源于APHEXDA产品的特许权使用费收入 - **净亏损**：260万美元 - **研发费用**：250万美元 - **一般管理费用**：90万美元 - **非经营收入**：50万美元 - **现金及等价物**：季度末余额1,740万美元 ## 2. 财务指标变化 **同比变化（2026年Q1 vs 2025年Q1）：** - **营收增长**：从30万美元增至50万美元，同比增长66.7%，主要
05-30 12:27
BioLine Rx Q1 Sales $477.000K Beat $343.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $477.000 thousand which beat the analyst consensus estimate of $343.000 thousand by 39.07 percent. This is a 87.06 percent increase over sales of $255.000 thousand
05-27 19:02
BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade Gliomas
GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment.In a comprehensive pre-clinical program, orally administered GLIX1
05-19 19:04
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers BioLine Rx (NASDAQ:BLRX) stock increased by 12.5% to $3.11 during Mond...
05-19 05:05
BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas
The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announced in September 2025. The patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief
04-28 19:13
BioLineRx Launches First Human Trial For Brain Cancer Drug
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase
03-26 19:17
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multi...
03-26 19:00
BioLine Rx Q4 Sales $194.000K Miss $651.598K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $194.000 thousand which missed the analyst consensus estimate of $651.598 thousand by 70.23 percent. This is a 98.35 percent decrease over sales of $11.749 million
03-23 19:16
Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell • Avalo Therapeutics (NASDAQ:AVTX) is likel...
03-23 19:11
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and mo...
03-23 19:00
